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ABSTRACT 
Mesenchymal stem cells (MSCs) are adult multipotent cells that due to their ability to 
homing to damaged tissues and differentiate into specialized cells, are remarkable cells in the 
field of regenerative medicine.  It's suggested that the predominant mechanism of MSCs in 
tissue repair might be related to their paracrine activity. The utilization of MSCs for tissue 
repair is initially based on the differentiation ability of these cells; however now it has been 
revealed that only a small fraction of the transplanted MSCs actually fuse and survive in host 
tissues. Indeed, MSCs supply the microenvironment with the secretion of soluble trophic 
factors, survival signals and the release of extracellular vesicles (EVs)  such as exosome. 
Also, the paracrine activity of EVs could mediate the cellular communication to induce cell-
differentiation/self-renewal. Recent findings suggest that EVs released by MSCs may also be 
critical in the physiological function of these cells. This review provides an overview of 
MSC-derived extracellular vesicles as a hopeful opportunity to advance novel cell-free 
therapy strategies that might prevail over the obstacles and risks associated with the use of 
native or engineered stem cells. EVs are very stable; they can pass the biological barriers 
without rejection and can shuttle bioactive molecules from one cell to another, causing the 
exchange of genetic information and reprogramming of the recipient cells. Moreover, 
extracellular vesicles may provide therapeutic cargo for a wide range of diseases and cancer 
therapy. This article is protected by copyright. All rights reserved 
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1. Introduction 
  In the past few decades, regenerative medicine employed various types of human stem cells 
for treatment of injured, malfunctioning tissues and organs. emerging evidence have shown 
that stem cell therapies are a promising strategy to improve regeneration in damaged tissues 
such as heart, brain, spinal cord, liver (1) . In addition, stem cell therapies can be considered 
as a hopeful approach for irreversible diseases which there is not any treatment options at this 
moment. Regenerative medicine strategies include using stem cell differentiation ability to 
reconstruct missed or damaged tissues and organs by a safe, effective transfer methods (2).   
The regeneration potential of stem cells such as mesenchymal stromal cells (MSCs), induced 
pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have established in order to 
restore human damaged tissues by means of secretion of growth factors, cytokines and 
extracellular vesicles. MSCs possess the particular advantages such as multi-lineage 
differentiation with immunomudulatory and immunosuppresion effects that make them as a 
safe effective stem cell-based therapy  in clinical setting (3). 
 Moreover, the paracrine activity of could account the regenerative ability of MSCs and one 
of the predominant components is extracellular vesicles (EVs) that possess the crucial role in 
their therapeutic potentialMSC-derived EVs therapy  display a desirable cell-free therapeutic 
option in regenerative medicine (4). EVs are naturally secreted membrane vesicles which 
referred to exosomes, microvesicles and apoptotic bodies. Mounting evidences show a great 
potential of EVs generated from MSCs as specific biomarkers for diagnosing, prognosis or 
prediction of diseases. Moreover, these vesicles can be used to treat many disorders through 
regenerative and immunoregulatory capacities or as a novel carrier in drug delivery systems 
to transfer drug agents or genetic materials (1, 5, 6). In this review, we aimed to discuss the 
beneficial therapeutic potentials of EVs for various diseases treatment.  
2. Mesenchymal stem cells and its phenotyping 
 A group of adult stem cells are MSCs which extensively studied as therapeutic tools in 
regenerative medicine. In 1968, Friedenstein and colleagues found this adult stem cells in the 
stromal compartment of bone marrow (7).  
The International Society for Cellular Therapy (ISCT) has considered the minimal criterion 
for multipotent human MSCs definition which include: (i) the adherent cells to plastic; (ii) the 
cells with fibroblast-like morphology which can differentiate under a certain stimulus into 
osteocytes, adipocytes and chondrocytes; (iii) positive expression of CD105, CD73 and 
CD90; negative expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and 
HLA-DR surface molecules (8-13). Human MSCs are also negative for CD4, CD8, CD11a, 
CD14, CD15, CD16, CD25, CD31, CD33, CD49b, CD49d, CD49f, CD50, CD62E, CD62L, 
CD62P, CD80, CD86, CD146 (vascular cell adhesion molecule [VCAM]-1), CD117, 
cadherin V, and glycophorin A, and positive for CD10, CD13, CD29 (b1-integrin), CD44, 
CD49e (a5-integrin), CD54 (intercellular adhesion molecule [ICAM]-1), CD58, CD71, 
CD146, CD166 (activated leukocyte cell adhesion molecule [ALCAM]), CD271, vimentin, 
cytokeratin (CK) 8, CK-18, nestin, and vonWillebrand factor (14) . Some surface markers are 
tissue specific for example; high levels of CD34 only express on adipose tissue-derived 
MSCs and CD27 could be found on bone marrow-derived MSCs. These criteria provide 
characteristics for MSC purification and their expansion by several-fold in-vitro, without 
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losing their differentiation capacity. Furthermore, colony-forming units of fibroblasts (CFU-
f) is another characteristic of MSCs that consist of  small colonies of low density plated cells 
which correspond to the progenitors that can differentiate into one of the mesenchymal cell 
lineages (15). MSCs have been used as the first kind of stem cells in clinical regenerative 
medicine after HSCs due to their easy isolation, rapidly ex vivo expansion, and also their 
autologous transplantation. These cells have other advantages including differentiation into 
multiple lineages, enhancing tissue repair, anti-inflammatory properties, and 
immunosuppression activities. Recently, the migration ability and incorporation of MSCs into 
specific tumors have been demonstrated in several different types of pre-clinical models 
which prove their potential as ideal anti-cancer agent’s carriers (10, 16). 
3. MSCs and immunomodulation 
 It's established that multipotent MSCs can differentiate into a wide variety of cells including 
mesodermal and non-mesodermal lineages. In addition to their differentiation potential, one 
of the best-explained  functional characteristics of MSCs is their immunoregulatory abilities 
(7). Though, the underlying mechanisms of MSC immunomodulation properties must be 
clarified. Numerous researches have provided data that show MSCs immunosuppression 
abilities. They can suppress proliferation of pre-stimulated T cell, differentiation of naïve T 
cells to effector cells, secretion of pro-inflammatory cytokines and also their cytotoxicity. 
MSCs have an ability to affect the cytokine secretion profile of T-cells, dendritic cells and 
macrophages. Furthermore, MSCs can regulate functions of regulatory T cells (Tregs), the 
balance of Th1/Th2 whereas they can suppress the function of other cells of the immune 
system. (17). Interleukin-2 (IL-2)-induced natural killer (NK) cell activation and the 
maturation, activation and antigen presentation of dendritic cells are suppressed by their 
immunomodulatory effects (16). MSCs express low level of complex class II (MHCII) and 
co-stimulatory molecules (B7-1and B7-2). They get involve with different types of the 
immune responses by means of cell-to-cell contacts. Besides, transforming growth factor-β1 
(TGF-β1), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), indoleamine-pyrrole 2, 
3-dioxygenase (IDO), nitric oxide (NO), matrix metalloproteinases, and interleukin 6 and 10 
have been considered as major modulator for MSCs immunosuppressive effects. Extensive 
proofs provide that interferon-γ  (IFN-γ), tumor necrosis factor-α (TNF-α), IL-1α or IL-1β 
which called inflammatory cytokine can mediate MSCs immunosuppressive activity through 
cyclooxygenase 2 (COX-2), PGE2 and IDO (18, 19). ProstaglandinE2 (PGE2)-derived MSCs 
suppress proliferation of T-cell and induce the T regulatory cells. IDO secreted by MSCs has 
been shown to suppress allogeneic T-cell responses and can induce tolerance after kidney 
allograft transplantation (20).it's published that MSCs heme oxygenase-1 plays an 
immunosuppresion role for suppression of T-cell proliferation and Toll-like receptor 
activation. HO-1activity can be regulated by iNOS and IDO. NO is another soluble factors 
that secrete by MSCs which involve in the T cell proliferation and STAT5 phosphorylation 
inhibition. Also, the proliferation of IL2–induced NK cells and the expression of NKp30 and 
NKG2D are inhibited via IDO and PGE2. Cell to cell contact is a main factor in MSCs 
immunomodulatory impacts. It's reported by Han et al that contact-dependent mechanisms 
may decrease the survival and proliferation of T cells whereas make increase the proportion 
of Tregs . IFN-γ upregulate MSCs Cell adhesion molecules secretion including CD274 (also 
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
known as Programmed death ligand 1), vascular cell adhesion molecule-1 and galectin-1 
which are involved in cell to cell contact and the promotion of MSCs immunomodulation 
capacity. However, MSCs apply both direct cell to cell contact and soluble factors for their 
widely different regulation.  These capacities make them as a promising candidate to control 
host-versus graft (HvG) and graft versus host disease (GVHD) in BM transplantation (16, 17, 
21-23). 
 
4. MSC in regenerative medicine 
New and emerging terms in biotechnology and medicine are tissue engineering and 
regenerative medicine which employed to depict generation of complex tissues and organs 
from simpler pieces. Sever or chronic disease treatment by novel therapies is a gold main of 
this field (24). The “regenerative medicine” term is more concentrate on the utilizing stem 
cells as therapeutic tool and self-healing abilities. MSCs are the great opportunity in the field 
of stem cell therapy due to their appealing characteristics such as a: their wide ranging 
differentiation ability into tendons, bone, cartilage, ligaments, muscles, and neurons. B: their 
easy accessibility. C: The Straightforward isolation and their relatively fast large- scales 
expansion of MSCs in a short period of time through culture. d: human clinical trials by 
MSCs show a  satisfactory results of both allogeneic and autologous MSC transplants due to 
their immunomodulatory effects (14, 25) . It's cleared that culture-expanded MSCs did not 
express MHC class II cell surface markers, but rather only MHC class I and no co-stimulator 
molecules (26) . Thus, human MSCs could not present antigen and would evade from host’s 
immune system (27). These observations were used to proposed that MSCs could be used as 
a therapeutic tool in the regenerative medicine to repair damaged tissues because of different 
mechanisms, for example, differentiation into damaged cells, microenvironment repair with 
paracrine/juxtacrine effects of cytokines, soluble factors and growth factors or reorganization 
of extracellular matrix (28). Source of MSCs isolation may influence on therapeutic 
efficiency. For example, Human MSCs-derived adipose tissue (AT-MSCs) xeno-transplant 
improve angiogenesis and axonal regeneration and better functional recovery than BM-
MSCs. AT-MSCs induced high levels of neurotropic factors such as BDNF, VEGF, and HGF 
(29).oseteogenesis potential of MSCs have been extensively studied and have been applied in  
bone repair and regeneration. They employ to treat bone disorders as osteogenesis imperfecta 
(30, 31) and engineering of bone tissue together “scaffolds” (32). The mesenchymal 
precursors osteogenic benefits depends on their differentiation potential into osteoblast but 
also on their ability to produce growth factors and cytokines to the damaged tissues thereby 
promote the regeneration process (33). Apart from MSCs advantages in bone repair, they are 
also used to involve in treatment of cardio- vascular diseases. MSC-based cell therapy can 
repair heart injuries by the production of new cardiomyocytes (34). However, there is 
currently no clear agreement if MSCs have differentiation ability into cardiomyocytes and, if 
so, by which signals. Some experiments haves been shown that small proportions of 
transplanted MSCs remain in the target tissues (35). It is believed that MSCs positive effects 
on heart disorders consist of differentiation capacity into cardiomyocytes, the release of 
trophic factors and inflammatory suppression properties. MSCs are also exploited for 
neuronal injury and neurodegenerative diseases treatment such as Alzheimer , Parkinson and 
Huntington diseases by means of  MSCs ability to locally secrete high levels of brain-derived 
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neurotrophic factor (BDNF), nerve growth factor(NGF), vascular endothelial growth factor 
(VEGF) and hepatocyte growth factor (HGF), indeed the expression of these factors have 
been increased in vitro when MSCs are exposed to injured brain extracts (36). Moreover, the 
immune response modulation by MSCs is a key factor for neurodegenerative diseases 
treatment (37). Recently, there are two different opinions regarding the impact of MSCs on 
cancer which have no clear consequences. Some showed that MSCs have tumor tropism 
activity, immune suppression capabilities and could be considered as a novel candidate for 
cancer treatment. However, others believe that MSCs may promote tumor growth through 
promoting angiogenesis, creating a niche to support cancer stem cells survival, increasing 
formation of metastasis by modulation of the immune response against cancer cells (7). 
4.1. MSCs in cancer therapy 
Cancer, or malignant neoplasm (new tissue), has known as a global health problem of 
epidemic proportion. The conventional techniques of cancer therapies (surgery, 
chemotherapy or radiotherapy) do not handle their limitations such as cancer recurrence, 
metastasis following initial remission because of the lack of selectivity. Also, the final cancer 
therapy aim is to advance anticancer agents with precise specificity which strongly target 
tumor cells while sparing normal cells (38). Many adult stem cells (SCs) have been shown 
intrinsic tumour-tropic properties, proposing them as a considerable candidate for targeted 
cancer therapy strategies. These strategies divided into two separate parts which include their 
site-specific migration towards micro-metastatic lesions and another is their genetically 
modification to express or release different anti-cancer agents, thereby solve the short half-
life of chemotherapeutic agents (39). Maximizing the therapeutic impact of SC therapy 
require which they escape through immune system towards malignant sites to make their 
therapeutic effects (40). While the advantages of MSCs in regenerative medicine is relatively 
well-found, MSCs using in anti-cancer therapy is getting developing attention (40). In 1993, 
Maestroni et al discovered the ability of MSCs tumor tropism which has led to a good 
agreement of MSCs role as a therapeutic agent in tumors. The cellular and molecular 
mechanisms that underlie MSC migrate across endothelium and home to the target tissues are 
far from being completely understood (41). To date, stromal cell-derived factor SDF-1 and its 
receptor CXC chemokine receptor-4 (CXCR4) are the key mediators of stem cell homing to 
tumor sites. The unmodified MSC have been noticed to have anti-tumor effects both in vitro 
and in different mouse models of cancer by means of releasing factors with anti-tumor 
properties that decrease glioma proliferation, melanoma, lung cancer, hepatoma and breast 
cancer cells. The migrations of Human MSCs to tumorigenesis sites suppress tumor growth 
in a mouse model of Kaposi's sarcoma. The anti-angiogenic effects of MSCs have been 
reported in melanoma models. Direct injection of MSC into mice bearing melanoma induced 
appotosis of tumor cells (38, 42). Moreover, MSCs properties such as tumor tropism and 
immunity granted nature make them a perfect anti-cancer drug delivery approach. The 
engineered MSCs effects which possess anti-cancer genes such as IFN-ß, IL-12, IFN-α, IFN-
gamma, IL-2, NK4 and TRAIL have been explored in different cancer models(39). In other 
hand, MSCs tumor tropism can be employed for oncolytic viruses delivery to tumor 
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locations. Some studies described the positive anti-tumor effects of oncolytic viruses 
delivered by MSCs when they have been injected to tumor sites in animals (43, 44) . 
4.2. MSCs in neurodegenerative disease 
Stem cell-based therapy is considered a novel approach for neurodegenerative diseases. In 
spite of a small number of stem cells with limited regeneration capacity within some special 
areas such as subventricular zone (SVZ) of the lateral ventricle wall and the subgranular zone 
of the hippocampal dentate gyrus, neural stem cells are not so appropriate for 
neurodegenerative diseases treatment regarding their less accessibility.(45). However, neural 
stem cells are not easy accessible cells for neurodegenerative diseases treatment.  Previously, 
several studies defined MSCs regeneration potential, differentiation abilities into all mature 
neural cell types and their easily isolation and expansion. MSCs have differentiation ability 
into all mature neural cell types. Especially, MSCs obtain new morphological properties, 
specific neural markers, and electrophysiological properties in neural progenitor maintenance 
medium which represent of neural differentiation (46). MSCs limit CNS tissue damages in 
animal models or have a mediator role in CNS tissue repair via replacement of damaged cell 
by means of differentiation or trans-differentiation through their paracrine functions. Many 
studies disclosed that secretion of protective factors from the injection site may provide 
therapeutic effect of MSCs by several classes of molecules including growth factors, anti-
inflammatory and immunomodulatory chemokines of transplanted cells (47). Therefore, the 
stem cell replacement therapies investigations for neurodegenerative diseases treatment such 
as Alzheimer disease (AD), Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), and 
multiple sclerosis (MS) became developing interests in regenerative medicine. In Alzheimer, 
as the most common reasons of dementia, losing various types of neuronal lineage cells occur 
in response to the production of amyloid-β peptide (Aβ) plaques and neurofibrilary tangles in 
different parts of the brain which finally result in cognitive impairment and loss of memory.  
Since available drugs do not have any significant effect on this disease, finding the new 
treatments is a crucial need. The authors found out that brain-derived neurotrophic factor 
increases synapse density and improving AD cognition through its important impact upon 
neuron outgrowth and synapse formation.(48). In addition, scientists have observed a 
neuroprotective effect in hemopoietic growth factors such as granulocyte colony-stimulating 
factor (G-CSF), erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), stem cell factor (SCF), vascular endothelial growth factor (VEGF), and stromal 
cell-derived factor-1-alpha (SDF-1-alpha) in ischemic stroke (49, 50). Lack of data in humans 
is the main problem appraising growth factors effect on neurodegenerative disease 
treatments, even though there are some promising information earned from animal model. 
Some hopeful results of MSCs therapy in patients with ischemic stroke have been reported by 
clinical trials which may explain their effect on increasing growth factors in AD patients in 
the future.(51). MSCs might also be considered a new therapeutic method for ALS that can 
provide or return function of motor neurons. It has been published that transplantation of 
MSCs resulting in their survival and migration towards lumbar spinal cord of SOD1G93A 
mice, astrogliosis inhibition, suppression of microglial activation and ALS-related decrease in 
the number of motor neurons, so cause to an amelioration of motor performance (52). 
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Parkinson is the second most common neurodegenerative disease which accompanies with 
loss of dopaminergic neurons in substantia nigra, and motor functions. Although some 
palliative treatments are used as the current treatments for this disease, the MSCs have also 
been proposed for protecting neural cell types. These treatments were used as a new way for 
PD treatment in a PD mouse model and it was shown that dopaminergic neurons and tyrosine 
hydroxlase-positive cells will survive after MSCs transplantation. (53). The morphology and 
differentiation of MSCs derived from PD patients are similar to normal MSCs. In addition, 
PD-derived MSCs can differentiate with certain stimuli into dopamine cells. Also, PD-
derived MSCs could suppress T cells proliferation which introduce MSCs as a promising cell 
for cell therapy (54). Pre-clinical experiments have been proposed that MSCs show also an 
effective therapy in animal models of myelin disease, such as multiple sclerosis, where MSCs 
might help to re-myelination and myelin recovery. Autologous naive BM-MSCs transplanted 
into PD in a pilot human study which followed for up to 36 months without any tumor 
formation evidences or side effects (45). Clinical studies of MSCs are a young field and there 
is a strong requirement to gather information related transplantation of MSCs and its efficacy. 
 
4.3. MSCs in cardiovascular disease 
Cardiovascular diseases (CVD) are considered as a serious problem which cause for one of 
the most leading mortality and morbidity worldwide. Despite the major improvement in 
cardiovascular diseases management it has failed to avoid myocardial scar formation and 
replacement of damaged cardiomyocyte mass with functional contractile cardiomyocyte. In 
the last decade, stem cell therapy for heart diseases has introduced as an alternative option for 
regeneration of lost cardiomyocytes and vascular endothelium in regenerative medicine. 
MSCs have been proven to be the most beneficial stem cells and their therapeutic 
applications for MI treatment is rising in comparison with other stem cells (55). Their 
outstanding characteristics including the ease of isolation from different tissues, possibility of 
their large-scale expansion, their differentiation ability into cardiomyocyte and vascular cells, 
their capability of homing towards the inflammation sites, their immunologically tolerance in 
recipient, the possibility of their systemically IV delivery without cardiac catheterization 
laboratories and the opportunity of using genetically modified MSCs to improve their 
engraftment or differentiation potentials make them a popular cell source (56) . It's revealed 
that MSCs express specific cardiac genes and show cardiomyocyte morphology and 
contractile activity on the exposure of 5-azacytidine. (24) . MSCs reduce the infract size and 
scar formation when implanted in an infracted heart and trigger myocyte regeneration. They 
exert their function via induction of vascular repair, angiogenesis, secretion of chemokines 
and ultimately stem cells homing. BM cells were administered for the first time for 
cardiomyoplasty in 1999 by Tomita et al. The autologous BM-MSCs injected 
intramyocardialy 3 weeks after cryoinjury. This cells home to injured sites and expressed 
muscle-specific proteins (57). Thereafter, various preclinical researches has been 
demonstrated left ventricular (LV) function improvement, reduction in infract size and 
mortality after MSCs transplantation in animal models such as mice, rats, swine, canine and 
sheep in acute or chronic MI (58). Schuleri et al designed a similar study through 
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intramyocardial MSC transplantation that showed LV function was increased. This result 
derived from improvement in myocardial blood flow and vessel size. The delivery methods 
and safety optimization are vital challenges of MSCs therapy in heart disorders. The majority 
of researchers have found that intramyocardial injection of progenitor cells in large animal 
models are safe and possible (59). On the other hand, dose relate investigations have found 
no directly results to date (60). furthermore, intramyocardial injections of high doses of 
allogenic MSCs have been displayed their safety in a swine  (61) and in another study 
reported that intravenous injection of MSCs altered the myocardium electrophysiological 
properties (62).  Although numerous studies have proven the beneficial effects of MSCs in 
heart regeneration, a number of publications have increased worries about tumor formation 
after BM-MSCs transplantation. The calcification and ossification is another serious concern 
of using MSCs and BM-MSCstem cells (63, 64). In contrast to these results, multi preclinical 
studies demonstrated their safety without any sign of tumor formation in large-animal models 
(65). According to this pre-clinical observation, some clinical trials have been done for heart 
injury treatment in patients. Some trials applied autologous bone marrow-derived 
mononuclear cells for MI treatment and reported that indicators of cardiac function have 
enhanced (66-68).  
 
4.4. MSCs in Respiratory diseases 
One of the serious health problems is lung diseases which lead to a high rate of mortality 
around the world.  Recently, treatment of lung diseases including chronic lung diseases, acute 
respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF) and chronic 
obstructive pulmonary disorder (COPD) faced obstacles and that there is no treatment option 
except lung transplantation (69). However, the rejection and immunosuppressive side effects 
remained as major problems of transplantation (70). The obstructive diseases avoid normal 
breathing by the fibrosis formation, airways or parenchyma inflammation and increase the 
resistance of airflow and compliance reduction. Also, chronic injuries disrupt the healing 
mechanisms lead to scar formation, fibrosis and loss of lung function  (71, 72). The present 
treatment strategies use current drugs, mechanical ventilation and transplantation for lung 
disease. In addition, scientists recently have focused on cell therapy as a new critical 
therapeutic option. Stem-cell based therapy is a promising substitution of transplantation for 
tissues or organ repair. MSCs have abilities to regulate immune systems, secrete some 
soluble factors such as growth factors and chemokines which allow them to play a key role in 
the decrease of inflammation, improving tissue repair and avoiding fibrosis through 
interactions with stromal and immune systems cells at in the damaged sites of the lung. The 
curative current treatment for acute lung diseases such as ARDS employs traditional fluid 
strategy (73) and ventilation protection methods but can't improve their mortality. Some 
investigations have been designed MSCs effectiveness on the endotoxin-induced ARDS 
animal models  (74). These studies proved that MSCs transplantation increases the survival 
rates through suppressing secretion of inflammatory cytokines such as IL-1β, TNF-α, and IL- 
6 (75, 76) and anti-inflammatory cytokines rising. Moreover, clinical trial results display 
MSCs therapy could decrease the C-reactive protein level in COPD patients. Emphysema is a 
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hallmark of chronic pulmonary obstructive disease which induced by vascular endothelial 
growth factor (VEGF) inactivation and also proinflammatory cytokines growing up (77). 
Thus, MSCs injection can be a great approach to treat chronic lung disease. Efficacy of 
MSCs therapy in IPF patients advanced its clinical trial phase, with multi incomplete trials 
that registered in “www.clinicaltrials.gov” and one completed trials in the phase I. Numerous 
animal models experiments have shown the MSC beneficial effects in the various lung 
disease that suggest they may have a good effects on Brochiolitis obliterans (BO) treatment. 
Also, their positive effects have been revealed to avoid rejection in heterotopic tracheal 
transplantation models. The excellent effects of stem cell therapy in animal models develop 
their application in human clinical trials as a novel treatment in different lung diseases (78, 
79). 
5. Limitation of stem cell therapy 
Regenerative medicine is using MSCs to treat a lot of disorders because of their great 
capabilities such as homing to injured and inflamed tissues, multi-lineage differentiation, and 
immunomodulatory effects on immune systems and even targeted-tumor therapy. There are 
some elusive problems which should be answered about the migration mechanisms of MSCs. 
It's understood that chemokines – chemokine receptors and MSCs adhesion molecules can 
improve the therapeutic strategies of ex-vivo expanded MSCs. Although, the safety and 
effectiveness of MSC therapy has been shown but still many aspects of their action 
mechanisms is not understood. However, there is an essential need to design studies of 
engraftment, homing and in vivo differentiation mechanisms and their long-term safety 
evaluation. MSC therapy makes some concerning challenges including their immune-related 
rejection, genetic instability, survival limitation and function restriction (82). Besides, these 
problems, tumor formation are a major issue of MSCs therapy in clinical applications.  The 
standard methods for ex-vivo expansion of MSCs, large-scale production, storage and 
distribution should be validated. The clinical-grade expansion needs a consistent expansion in 
vitro, which can increase risks of genetic instability and production of transformed cells (83). 
It’s investigated that upregulation of c-myc, expression of p-16 and telomerase activity may 
involve in MSCs transformation. Furthermore, genetic manipulation of MSCs raises their 
oncogenic potential because the transgene can disrupt the genome stability which has been 
demonstrated in some tumors such as gastric adenocarcinoma (84), lipoma (85) and 
osteosarcoma (86). In addition, novel-engineered tools for cell delivery to specific tissue 
should be produced such as cell-covered stents and catheter-based delivery in heart disease.  
In the light of these results, clinical MSCs should be exactly explored to make clear its 
cautionary challenges. 
 
6. MSCs release extracellular vesicles as a novel approach of cell free therapeutics 
 MSCs are believed to exhibit therapeutic impact through a different mechanism of actions in 
response to occurring tissue damage. They could be activated and also recruited to the site of 
injury by signal sensing due to their widespread perivascular niche. New studies demonstrate 
that MSCs could be contributed in regeneration via exhibition of two crucial function 
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“replacing of diseased cells” by differentiation to resident target progenitor cells or more 
recently “cell empowerment” something beyond cell to cell contact (80). Despite of low cell 
retention time within a few hours and also poor engraftment in target organ, satisfactory 
therapeutic results have been observed after cell transplantation in cell-based therapies (81-
84). Many investigators attribute therapeutic effect of MSCs mostly to their paracrine effect, 
particularly, through the secretion of extracellular vesicles (EVs) as medicinal cell-free 
products (85-96). Interestingly, uncovering the latest function of MSCs led to exploiting 
regenerative roles of MSC-derived EVs in regenerative medicine. Due to EV-carrying 
bioactive cargoes including nucleic acids, proteins, metabolites and lipids, by exchanging 
biological properties between cells, they could be involved in numerous normal physiological 
and also pathological conditions (97-100). Furthermore, EVs generated from MSCs have 
been reported as a targeted delivery vehicle through transferring of exogenous biological and 
chemical molecules in gene and cell-based therapeutics (85, 86). Recently, studies shows that 
EVs generated from MSCs could recapitulate their parent cell pleiotropic functions such as 
cell proliferation (101), anti-inflammatory and immunomudulatory (102, 103),  anti-fibrosis 
(86) and also anti-apoptosis (89) in preclinical studies and also translation to EV-based 
clinical trials (92) in a wide range of diseases. 
6.1. Extracellular vesicles: Exosomes and microvesicles 
Extracellular vesicles were firstly discovered during maturation of sheep reticulocytes (104). 
These nano-sized bilayer membranous vesicles are produced and secreted from various cell 
types, in particular, MSCs (100, 105-107). Recently, the interest in EV research has been 
exponentially raised and most of the efforts have been paid on understanding the beneficial 
function of MSC-derived EVs of other cell types. In order to harmonization and clarification 
of vesicle nomenclature and terminology, the International Society for Extracellular Vesicles 
(ISEV) in 2011 suggested “Extracellular vesicle” (EV) as a general term for all membranous 
vesicles which are released to the surroundings. Extracellular vesicles are categorized to 
exosome (EX), microvesicle (MV) and apoptotic body based on their biogenesis pathways. 
Exosomes and microvesicles have been described two important subpopulation of EVs which 
most of researches have focused on their origin/biogenesis, size distribution, component and 
biological function. Exosomes comprise small membranous vesicles and they range 30 to 120 
nanometers in size, whereas, microvesicles are partially larger vesicles and their size range 
between 50 nanometers to 1 micron.  
Exosomes are regarded as homogenous population of vesicles generate by inward budding of 
the late endosome or multivesicular body (MVB) through the endosomal sorting complex 
required for transport (ESCRT)-dependent or independent mechanism. Some other proteins 
such as programmed cell death 6 interacting protein (PDCD6IP; also known as ALIX) and 
tumour susceptibility gene 101 protein (TSG101) are also involved in exosome biogenesis 
(108-110). They are subsequently secreted post-fusion to the cell membrane which mostly 
depends on activity of several Rab GTPase proteins (111).  
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Moreover, microvesicles and apoptotic bodies have been described heterogeneous EV 
population in size range. They are directly released via budding outside of the cellular 
membrane by regulatory proteins such as ADP-ribosylation factor 6 (ARF6) (112, 113).  
6.2. EV Components and biological functions  
Extracellular vesicles that are released in cellular microenvironment could influence on local 
adjacent cells or even distant cells systematically. EVs contain a complex set of molecules 
(proteins, mRNAs, miRNAs, DNAs and lipids) depending on their cell of origin, therefore, 
they contribute to cellular and biological processes such as self-renewal, differentiation, 
migration, extracellular remodeling, reduction of oxidative stress, angiogenesis and 
inflammation. Moreover, significant regenerative impact of MSC-derived EVs have been 
reported in myocardial ischemia (88), acute liver failure (ALF) (86, 114), acute kidney injury 
(AKI) (89), neurological disorders (115), wound healing (116) and graft versus host disease 
(GvHD) (92) owing to vesicle content. Therefore, investigation of critical molecules of EV 
cargos may provide new insight to EV-mediated beneficial mechanism. High-throughput 
mass spectrometry-based analysis of proteins revealed some surface receptors (CD105, 
CD73, CD29, CD81 and CD44), signaling molecules (which are involved in controlling of 
TGF-β, BMP, MAPK and PPAR recipient cell signaling pathways), adhesion molecules and 
MSC-associated markers which may account for therapeutic potential of MSC-derived EVs 
(117, 118). In addition, another study showed that MSC-derived MVs highly expressed 
angiogenesis and migration associated cytokines and ckemokines. For example, enhanced 
expression of Interleukine 6 (IL-6), vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF) as proangiogenic proteins and monocyte chemokine protein-
1 (MCP-1) as migration-promoting chemokine to inflammation were determined in MSC-
derived MVs content using immunoblot analysis (119). Recently, high-resolution analysis of 
MSC-derived EX/MV demonstrated that EX and MV could be distinguished in the context of 
proteomics.  Most common pathways such as immune response, heparin binding and 
integrins were enriched in EX, however, mitochondrial, proteasomal and endosomal 
reticulum-associated proteins were enriched in MV (120). Interestingly, the result showed c 
MSCs, their restricted expansion has been shown avoiding their large-scale production for 
clinical application (121). Subsequently, multi investigation have been explored an 
alternative strategy to produce MSCs. it's reported  that secretion of growth factors, miRNAs, 
and EVs effects on the biological properties of stem cells including stem cell regeneration,  
differentiation  potential and immunomodulatory roles (122). Interestingly, the regulatory 
factors secreted from condition medium of MSCs improved the kidney and myocardial 
damages in animal model (123).  Last several decades, MSCs immunoregulatory effects such 
as suppression of T and B cells proliferation, inducing tolerant dendritic cells (DCs), anti-
inflamatory cytokines secretion have been demonstrated  (124) .Moreover, MSC-derived EVs 
inhibit immune reactions through reduction of inflammatory cytokines and increasing of anti-
inflammatory responses in same way to MSCs but the underlying mechanisms are still not 
cleared (125). Recently, Fattore et al., discovered that MSC-EVs display strong 
immunosuppression activity as MSCs by T cell apoptosis, increase T reg population and the 
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release of interleukin-10 (IL- 10). Also, MSCs-derived EVs down regulate TNF-a  and IL-1b 
that are inhibitory factors for T cells maturation  (126). 
6.3. EV purification, storage condition and characterization 
In order to get reproducible results of extracellular vesicles in preclinical and clinical studies, 
obviously, attention must be paid towards standardization of methods used for sample 
collection, isolation and also characterization of EVs (127, 128). Therefore, to minimize non-
EV contamination, ISEV suggested minimal criteria to get a high yield and pure population 
of EVs. 24 to 48 hours serum free or EV-depleted serum containing conditioned media has 
been suggested for EV collection (129). 
There are several methods such as ultracentrifugation, density gradient, ultrafiltration, 
immuno-affinity, polymeric precipitation and microfluidics have been reported for isolation 
of extracellular vesicles (129). Of above mentioned methods, differential ultracentrifugation 
is assumed to be a gold standard procedure displaying high amounts of yield and low/medium 
pure EVs. However, density gradient is considered as a second commonly applied protocol 
generating low/medium yield and high pure EV subpopulation (130).  
Based upon the limited published studies have explored yet, EVs suspended in PBS buffer 
should be stored at -80◦C until additional experiments (128). Nevertheless, disruption and 
loss of function have been observed after defreezing of EVs (128). Thus, it is not clearly 
determined that temperatures -80 or below that could have an impact on structure and 
functional properties of EVs. Besides, it cannot be claimed that whether fresh or freeze-
thawed sample is preferred for clinical application. It seems that further research is needed to 
define optimum storage condition.  
Among different quantification methods of EVs, Nanosight Tracking Analysis (NTA), 
Dynamic Light Scattering (DLS) and also BCA assay are reported to be mostly used for 
vesicle size and/or amount and protein concentration, respectively. Unlike DLS technique 
which is able to get only particle size, both size distribution and EV number are defined by 
NTA (131).  Additionally, Electron microscopy is used to visualize the cup-shaped sphere 
morphology of EVs (132). Protein expression in EVs such as Alix, Tsg101 and tetraspanins 
including cluster of differentiation markers (CD9, CD81 and CD63) could be determined by 
western blotting and flow cytometry techniques. Based upon ISEV criteria it is suggested to 
examine at least three of mentioned proteins in order to ensure the purity of EVs (127).  
7. Exosomes as gene delivery vehicles 
Extracellular vesicles such as exosomes and microvesicles are harboring of DNA, mRNA, 
mirRNA, siRNA, proteins and showing a potential mode of intercellular 
communication(133). EVs are safe and biocompatible nanoparticle delivery tools from 
endogenous and exogenous nucleic acid sources. EV fraction extracted from HBV-infected 
cells contains abundant HBV DNA with the lack of HBsAg and could be transmitted to 
primary hepatocytes. This transmission by EVs is resistance to antibody neutralization and 
may be contributes occult hematite infection apart of HBV S gene mutants(134). 
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Communication between leukemic cell and normal blood cell with EV containg leukemic 
DNA increase malignancy and novel therapeutic targets to suppress tumor progressions(135). 
exoDNA is an important DNA appear in the circulation in early stage of cancer,  and could be 
serve  as a biomarkers. Intrestingly, circulating cell-free DNA is obtained from apoptosis and 
necrosis of tumor cells, which are belong to later stage malignancies(136). In glioblastoma 
multiform (GBM), EV secreted from tumor cells can cross from blood brain barrier,So they 
could be used to detect specific molecular mutation such as IDH1G395A(137). EVs derived 
from cardiomyocyte have DNA and RNA that induce 333 gene profile changes including 
suppressive and inductive effect, could change metabolic profile in target cells (138). 
Exogenous dsDNA loaded to EVs by electroporation method is limited to the size of DNA. 
The size limitation for this method is up to 1000 bp, however, for transfection methods is 4.5 
-10 kbp. Transfection method has a lower efficacy than electroporation(139).  Genetically 
modified cells that produce therapeutic EVs like prodrug-activating enzymes are assumed 
novel cancer vaccines for tumor cell. Mizrak et al. used MVs that express gene mRNA and 
protein–cytosine deaminase join to uracil phosphoribosyl transferase for the treatment of 
schwannomas in mouse models. This enzyme converts pro-drug (5-fluorocytosine (5-FC)) to 
5-fluorouracil (5-FU) as an effective anti-cancer drug (140). Y RNA fragments as a non-
coding RNA  in high level in EVs, have an anti-inflammatory by inducing of IL-10 
expression and cardioprotection effect(141). siRNA loaded in EVs by  transfection methods 
can be used for the silencing of Huntingtin gene and protein.  Glyceraldehyde 3-phosphate 
dehydrogenase(GAPDH) siRNA and (beta-secretase 1) BACE1 siRNA loaded into 
engineered dendritic cell-derived EVs delivery was exhibited the strong mRNA (60%) and 
protein (62%) knockdown of BACE1 and had therapeutic effect in Alzheimer ‘disease, in 
animal models(142, 143). MicroRNAs (miRNAs) are small conserved RNA molecules can 
decrease protein levels by degrading the mRNA or stopping the translation of the target gene. 
Exosomes deliver miRNAs to target cells, which reduces the levels of miRNA-target genes. 
MVs containing miR-29a/c significantly decreased the growth rate of the vasculature and 
tumors in gastric carcinoma(144). EVs derived from fibroblasts transfected with  miR-195 
led to decrease the size of cancer tumors, and improve survival of treated animals(145). 
 Modified and unmodified EVs have been exploited to achieve therapeutic effects. In 
modified cases, EVs are isolated from engineered cells and to be containing a specific 
mirRNA or siRNA that suppress specific mRNA, reduce inflammation or inhibit tumor 
growth. miR-124 and miR-145 have been transfected into MSCs, and these engineered MSCs 
released EVs containing miR-124 or miR-145, which induced the differentiation of neural 
cells in pathological conditions(146). EV- Let-7 targeted to EGFR-expressing cells provide a 
platform for clinical use of miRNA molecules to deliverantitumor miRNA to cancer tissues 
in vivo (147). In addition, promising results employing EVs as nucleic acid vectors to 
attenuating of HCV replication and expression of its receptor CD81, control obesity and 
immune responses have also been reported (148-150) (table 1). 
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8. MSC EVs as drug delivery vehicles 
 Drug delivery system (DDS) is a key technology to achieve effective and safe medication, 
since without DDS, therapeutic agents can easily distribute throughout the body and affect 
non-disease sites (151). An exciting and promising novel approach for efficient drug delivery 
is EVs. EVs can be used to deliver small pharmaceutical or biological molecules and pass 
major biological barriers such as the blood–brain barrier (BBB). At present, the well-known 
and ideal cell that has a scalable capacity to produce massive amounts of EVs is MSC. The 
use of EVs as new natural vesicles and ideal non-cell-based treatment strategy as delivery 
vehicles are being grown. Research has shown that MSC EVs as an ideal delivery vehicles 
are benign and non-immunogenic that unlike another cell sources of EVs such as dendritic 
cells (DCs) would not elicit immune rejection response or adverse effect when used as drug 
delivery vehicles (9). 
 
8. Advantages of EVs relative to other synthetic vesicles 
 EVs have many characteristics of an ideal delivery vehicle and can be as favorable 
alternatives to liposomes and other synthetic vesicles as drug delivery vehicles. Unlike 
synthetic vesicles, EVs have the distinct advantage, firstly, their natural origins that have 
protein and genetic materials (such as mRNA and miRNA) in their constructions which 
suggest EVs could be loaded by such biological materials and make them promising drug 
carriers, secondly, EVs are well tolerated and less toxic in the body as evidenced by their 
ubiquitous distribution in biological fluids such as blood, saliva, urine, cerebrospinal fluid, 
amniotic fluid, bile, and breast milk and thirdly, EVs have long half-life in circulation and a 
notable intrinsic capability to home to target tissues. MSC EVs-mediated drug delivery is 
likely to be biocompatible and would not elicit immune rejection response or adverse effect 
(9). 
 
9.1. Exosomes loading (in vitro- in vivo) 
Extensive research has been carried out using exosomes as vehicles for drug delivery. 
Efficient delivery of substantial number of therapeutic cargo from EVs highly depends on a 
successful method of their loading (152). Several strategies can be utilized for loading 
therapeutically active cargo molecules into extracellular vesicles (EVs): (A) loading EV-
producing cells with a therapeutic agent or in vivo drug loading, which is then released in 
EVs, recently researchers have shown that MSCs are able to uptake and then release 
entrapped drugs and suggested that MSCs are a promising factory to develop drugs with a 
higher cell-target specificity (Stem cell-extracellular vesicles as drug delivery systems: New 
frontiers for silk/curcumin nanoparticles (153), (154), (B) transfecting/infecting EV-
producing cells with DNA encoding therapeutically active compounds which are then 
released in EVs; it was reported that miR-122- transfected adipose-derived MSC is able to 
effectively package miR-122 into secreted exosomes and increase chemosensitivity of 
hepatocellular carcinoma through alteration of miR-122-target gene expression (155), and(C) 
In vitro drug loading refers to drugs loading into naïve EVs. Different procedures for drug 
incorporation in EVs were proposed including incubation, freeze/thaw cycles, 
electroporation, sonication, extrusion, and permeabilization with saponin (Figure 1). 
Doxorubicin and paclitaxel as two potent chemotherapeutic agents were loaded into EVs 
released by macrophages in 3 ways including incubation at room temperature (RT), 
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electroporation, and sonication (156). In 2015, Haney et al. applied sonication to EVs to load 
catalase and demonstrated a significant loading enhancement compared to permeabilization 
with saponin, freeze-thaw cycles, sonication, and extrusion (157). EVs act as messengers and 
interact with target cells to induce changes in their physiology. Some studies have shown the 
interaction of EVs with recipient cells by suitable techniques, such as flow cytometry, 
fluorescence microscopy. EVs can be interacted by target cells through mechanisms 
including ligand/receptor pairs and fusion with the plasma membrane, phagocytosis, 
endocytosis or micropinocytosis. For instance, LFA-1, a specific ligand on DCs can capture 
ICAM-1-bearing DC-EVs. In some cases, induction of physiological changes occurs after 
binding of EVs to recipient cells, for instance during the presentation of MHC–peptide 
complexes to primed T cells or NKG2D ligands to NK cells. In other cases, transferring of 
content of EVs inside the recipient cell induces physiological changes. It depends on the 
recipient cells, phagocytosis in macrophages, receptor-mediated endocytosis in DCs, 
macropinocytosis in microglia, lipid raft–dependent endocytosis in endothelial and tumor 
cells(157) (Figure 1). 
 
  
 
 
10. EVs rout of administration models   
Since understanding of communication between cells by EV and details of their biogenesis 
and release lead to improved diagnosis, early detection and novel therapeutic possibilities in 
some diseases. EVs can be used for delivery of drugs and genes as described previously. EVs 
can be administrated in intravenous injection, Subcutaneous/intravenous, intranasal and in 
situ injection and followed in vivo (158). For instance, administration of exosome contained 
supper paramagnetic iron oxide nanoparticles into the footpad resulted in EVs localization 
into lymph nodes with magnetic resonance tracking (159). The intravenously injected 
exosomes loaded with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) siRNA for 
specific knockdown of the GAPDH gene and delivering the APP cleaving enzyme (BACE1) 
siRNA, down regulation of the BACE1 protein in the brain was achieved in mouse model of 
Alzimers disease (143). In another research intranasal administration route of curcumin-
loaded exosomes from different cell types were capable for transversing of the blood brain 
barrier (BBB) and selectively taken up by microglial cells and induce apoptosis. In result 
exosomes inhibit brain inflammation and autoimmune responses in a model of experimental 
autoimmune encephalomyelitis and rapidly showed effectiveness. In this experiment, 
exosomes represented a safe and efficient delivery tool by crossing the BBB noninvasively 
and without being immunogenic (160).  Moreover, intravenous administration of MSCs-
derived EVs significantly improved functional recovery, rescued pattern separation and 
spatial learning impairments, promoted neurovascular remodeling (angiogenesis and 
neurogenesis) and reduced neuro inflammation in TBI animal models (161). Systemic 
administration of cell-free MSC-generated exosomes from tail route improves functional 
recovery and enhances neuron remodeling, neurogenesis, and angiogenesis. Based on results, 
axonal density and synaptophysin-positive areas were significantly increased along the 
ischemic boundary zone of the cortex and striatum in stroke rats treated with exosomes as 
EVs compared with PBS control as data shown with histopathology and 
immunohistochemistry (162). However, recent evidences, obtained following miR-155 
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loaded EVs expression, suggest that, in the blood, EVs are detectable as early as 5 min after 
intravenous administration with subsequent distribution in the liver, adipose tissue, lung, 
muscle and kidney, then decrease to less than 50%  during 30 minutes, and become 
undetectable after 4 hours (163), so it is crucial to use proper and accurate route for 
administration , biodistribution, trafficking analysis of exogenously administered MSCs-
derived EVs to receive more effective therapeutic response.  
 
11. EVs as a tool for diagnosis and therapy 
EVs carry nucleic acids and proteins from their host cells that are indicative of 
pathophysiological conditions of host cell. EVs have been recently involved in intercellular 
communication and in a variety of biological processes such as modulation of immune 
response, signal transduction, transport of genetic materials. They can be isolated from body 
fluids such as plasma, urea, blood, saliva, breast milk (164). EVs are widely considered to be 
important tool for biomarker discovery in early detection and also therapy of various diseases 
such as cancer and neurodegenerative diseases. Characterization of biological parameters 
such as protein, nucleic acid or even CD markers and lipid composition seriously are crucial 
for EVs potential applications. Early diagnosis of many cancers will not be possible. 
Therefore, it is of outstanding interest to look in more detail to the EV cargo (i.e. proteins, 
miRNA, mRNA) as they provide tools to monitor the status of the relevant producer cell. In 
this respect, the exploitation of comparative omic studies is fundamental for the detection of 
new biomarkers. For this reason, in proteomic and lipidomic analysis could significantly 
appliance the use EVs for theranostic (the combination of both therapeutic and diagnostic) 
approach (165). Expression level can be evaluated for diagnostic traits in compare of healthy 
conditions in various human diseases such as cancer or targeted for therapeutic application 
(166, 167). These nanoparticles can indicate the medical state of patients because of 
correlation between parent cell and biomarkers. For instance, it was revealed that panels of 
eight EV-associated proteins were up regulated in the urine of patients with bladder cancer 
compared to healthy subjects (168). Likewise, miRNA profiling of plasma-derived EVs 
identified a panel of four tumor-specific miRNAs of potential use in a screening test for lung 
carcinoma (169). MSC-EV can mimic the effects of their parental cell. Compared to cells, 
MSC-EV is very smaller and has lower possibility of rejection. For example based on Lau et 
al. in 2013 indicated that exosomes isolated from saliva may provide is criminatory 
biomarkers for pancreatic cancer (170). Also, Elements released by malignant cells such as 
oncogenic proteins and miRNAs, which can traverse via EVs to the tumor microenvironment 
and transfer of oncogenic activity to non-malignant cells. For example, mRNA and miRNA 
arrays have been employed to identify mRNAs and miRNAs associated with melanoma 
progression and metastasis in extracellular vesicles derived from melanoma. Identified RNA 
biomarker candidates are validated using quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR) (171). MSC-EVs could recaptulate the effects of 
MSCs in tumor therapies.Therefore; MSC-EVs are as alternative strategy that could 
overcome the limitations of cell-therapy approaches. In addition, due to their small size and 
transfection efficiency, EVs can act as proper nano vehicle for delivery of for example cancer 
or neurodegenerative disease drugs. These lipid vesicles could be engineered to deliver 
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therapeutic agents to target sites. For instance, it has been reported that the EVs secreted by 
SR4987 cells as mesenchymal cell model primed with paclitaxel (SR4987PTX) delivered 
active drugs and inhibited human pancreatic adenocarcinoma cells proliferation in a dose-
dependent manner. This experiment demonstrated that MSCs are able to package and deliver 
active drugs through their micro vesicles, suggested the possibility of using MSCs as a 
factory to develop drugs with a higher cell-target specificity (154). Currently some database 
are available for recording diagnostic result of EVs content for various disease, i.e., 
Vesiclepedia (www.microvesicles.org), EVpedia (www.evpedia.info) and ExoCarta 
(www.exocarta.org)  (172). 
Moreover, EVs have also the potential to serve as a noninvasive intervention for successful 
delivery of therapeutic agents such as drugs and siRNAs to the brain. Immunotherapy 
represents one of the most investigated aspects in EV-mediated therapy. It is also well 
determined that most of the mis-folded proteins associated with neurodegeneration such as 
superoxide dismutase, α-synuclein, amyloid and tau - involved in amyotrophic lateral 
sclerosis (ALS), Parkinson’s disease, Alzheimer’s disease and tauopathies, respectively, are 
carried via EVs, which can be considered as novel biomarkers for neurodegenerative diseases 
and interpret such neuronal EV (nsEV) analyses to neural clinical diagnostic applications and 
drug development. (158, 173).  Although exosomes do not replicate as an independent entity, 
but they can facilitate movement and spread of infection (bacterial or viral) through blood 
and tissues and could cause the effect in gene expression in the recipient cells through the 
classical toll-like receptor and NFκB pathway. In this regard EVs that can target certain tissue 
types and can protect them from the immune system are more preferred than liposomes, as 
they also have a longer half-life. So, EVs can be utilized for diagnosis or therapeutic aspects 
of infectious disease particularly in the pathogenesis of HIV to prevent from transmitting of 
infection (174). It has been shown that the level of EVs circulating in blood is significantly 
elevated in cancer patients. EVs vesicles purified from urine could be used for monitoring of 
the status of prostate cancer patients, because they contain elevated levels of 5T4 oncofetal 
trophoblast glycoprotein, prostate-specific antigen, and prostate-specific membrane antigen, 
relative to normal urinary EVs (175). Based on mRNA expression level analysis for diagnosis 
of cancer, extracellular vesicles purified from urine of prostate cancer patients, show 
increased expression of prostate cancer antigen-3 and transmembrane protease serine 2- 
transcriptional regulator ERG gene fusion (176). Furthermore, gastric cancer, glioblastoma, 
and lung cancer may also be detected using EVs, which show elevated expression of several 
cancer biomarkers including extracellular matrix metalloproteinase inducer, hepatocyte 
growth factor receptor, human epidermal growth factor receptor-2, and melanoma-associated 
antigen-1 for gastric cancer (177), prominin-1 for glioblastoma (178), and leucine-rich a-2- 
glycoprotein for lung cancer (179). In addition, circulating extra cellular vesicles purified 
from the blood of glioblastoma patients contain epidermal growth factor receptor variant III 
mRNA (180). Circulating EVs purified from the blood of gastric cancer patients exhibit 
significantly higher levels of mRNAs encoding melanoma-associated antigen-1 and human 
epidermal growth factor receptor-2 (177). The level of miR-21 is increased in circulating 
extracellular vesicles of patients with ovarian or esophageal cancer. In addition, levels of 
miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, as well as miR-214 are 
increased in the circulating EVs of ovarian cancer patients (181). 
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However, further studies are warranted for clinical and commercial application of the use of 
circulating EVs for cancer diagnosis and monitoring. Experimental biomarker sources and 
several proteins or RNAs in EVs have been found to be useful in monitoring of wide range of 
disease. But it is necessary to standardize the technique of EVs manipulation for their 
application in therapy and long-term EVs effectiveness in the treatment of human disease.  
 
12. Application of EVs derived from MSCs in regenerative medicine 
12.1. Immune disease treatment 
MSCs can manage immune systems response through cell-cell association and discharge of 
paracrine molecules. It's trusted that MSCs select inhibitory chemokines and stifling ligand-
receptor associations to assume a noteworthy part in immunosuppression and T cells 
movement direction(182). In agreement to understood MSCs immunoregulatory impacts, 
MSCs-determined EVs including microvesicles, exosomes and apoptotic vesicles have 
likewise been shown immunological concealment movement by enlistment of mitigating 
cytokines levels and diminishing of provocative chemokines which make them a contender 
for immune disorders treatment(10). What's more, MSCs-derived exosomes can likewise 
hinder Toll-like receptor signaling and activation that identified with innate 
immunomodulatory activity of MSCs(183). At the point when MSCs-inferred exosomes 
infused into a hypoxic pneumonic hypertension demonstrate, the inflammation suppress 
through pro-proliferative signaling, for example, phosphorylation of STAT3(184). The 
various consequences of EVs immunomodulation activities make EVs awesome 
immunotherapeutics alternatives. The extracellular vesicles (EVs) emitted by both 
prokaryotic and eukaryotic cells can convey molecular patterns of pathogen-related and 
injuries related, cytokines, autoantigens and the catalysts identified with tissue corrupting. 
What's more, EVs may be connected to diagnostics and focused on treatment in the 
incendiary and immune diseases (185) .In view of this speculation, MSC-derived exosomes 
possess an induction of peripheral tolerance. The segregated Microvesicles from co-culture 
amongst MSC and splenic mononuclear cells could hinder autoreactive lymphocyte 
multiplication and arrival of interleukin (IL)- 10 and transforming growth factor (TGF)- β in 
autoimmune system encephalomyelitis mouse display. Likewise, MSC-derived microvesicles 
have been broke down by flow cytometric techniques which its outcomes have demonstrated 
these cell-items can be a transporter for tolerogenic molecules including PD-L1, Gal-1, and 
TGF-β. This trial data recommend that MSC-derived EVS are strong organizer for peripheral 
tolerance induction and direction of invulnerable responses, which thought a novel obstinate 
hopeful as opposed to utilizing MSCs in immune system sicknesses treatment(186).  
Powerful techniques have been examined EVs anti-inflammatory properties for Rheumatoid 
Arthritis (RA). The transplantation of autologous adapted serum (ACS) exosomes intra-
articular seems useful impacts on RA treatment with diminished agony in joints and 
decreased markers of inflammation markers in the blood test. ACS-derived exosomes will be 
a promising and safe treatment for different sicknesses identified with the chronic 
inflammation or autoimmunity because of RNA and protein transfer.. MSC-MVs smothered 
multiplication in the receptive lymphocyte and furthermore IL-10 and TGF-b emission 
Correspondingly, exosmes got from MSCs were utilized as a part of lupus murine model and 
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were critical to ensure MSCs function.(187). As of late MSC-derived exosomes have been 
infused in mouse models of allogeneic skin grafting which prompt expanding Treg levels and 
put off GVHD for two days. In vitro  explores revealed that the enactment of MYD88-
subordinate motioning in monocytes gave by exosomes expanded Tregs cells (182). Clinical 
utilization of MSC exosomes in a patient therapy-refractory graft-versus-host disease proved 
their efficacy demonstrated their adequacy and 4 months following up of appearances 
identified with mucosa and cutaneous enhanced while immunosuppression organization 
diminished. Every one of the perceptions present the MSCs exosome potential for 
autoimmune treatment and immunotherapy however more examinations is required to assess 
their and advantages and disadvantages, viability and security for immunomodulatory 
purposes (188, 189). 
 
12.2. Cancer therapy 
Several studies have reported that EVs are potential candidates for the treatment of different 
tumors. Zitvogel and colleagues were the first researchers who have used tumor peptide-
pulsed dendritic cells (DCs) EVs as an alternative to DC adoptive therapy against tumors. 
Some studies have demonstrated that MSC derived EVs have a strong tropism to tumor 
environment such as their cellular origin which can provide a promising therapy for cancer 
treatment. It has been shown that MSC derived EVs can induce cell death by apoptosis in 
HepG2 (hepatoma) and Kaposi’s sarcoma cancer cell lines, while necrosis has been seen in 
ovarian cancer cell line (Skov-3) after MSC EVs treatment (190). EVs can pass the blood–
brain barrier and have been demonstrated to deliver genetic materials contained within to 
brain. These nano-vesicles are non-viable and the risk profile of EVs is thought to be less 
than that of cellular therapies. The natural ability of EVs to transport RNA suggests that these 
particles can be useful in gene- based cancer therapy to deliver therapeutic short interfering 
RNA (siRNA) and miRNAs to the target cells. Shtam et al. reported that EVs can deliver 
RAD51- and RAD52-siRNA into fibrosarcoma cell line and induce both gene knockdown 
and the massive reproductive cell death (191). EVs derived from the high expression of 
tumor suppressor miR-146b MSCs, inhibited glioma growth in a xenograft model (192). Two 
other studies also showed EV-delivered tumor suppressor miRNAs, let-7a and miR-143, 
inhibited tumor growth of breast and prostate cancer in vivo, respectively (147), (193). 
Migration of osteosarcoma cell has been reduced by EV-formed miR-143 (194). Munoz et al. 
have reported glioblastoma was more sensitive to chemotherapy after delivering anti-miR-9 
through MSC EVs (195). In 2014, Pascucci et al. showed that MSCs as a factory are able to 
package and deliver paclitaxel through their MVs and possessed strong anti-proliferative 
activity on the human pancreatic cell line (CFPAC-1) (185). EVs from dendritic cells loaded 
with a chemotherapy agent doxorubicin inhibited the growth of breast cancer xenograft 
tumors in vivo (196). MSC derived EVs can acquire strong anti-tumor activity after priming 
with anti-cancer agents. EV as an endogenous and promising vehicle for delivering active 
molecules, such as chemotherapeutic agent, growth factors and genetic molecules, 
specifically to the tumor microenvironment in cancer. 
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12.3. Neurological disease 
There are strong evidences that EVs, and in particular endosome-derived exosomes 
contribute to homeostasis in the CNS. Neurons communicate with each other through the 
secretion of EVs contributing to local synaptic plasticity, but EVs may also allow longer 
range communication within the CNS and influence neuronal networks located at a distance. 
In CNS-associated diseases, EV biogenesis, transfer or composition can alter, and cause 
pathology (165). Altogether, the EVs contribute to the local proliferation of 
neurodegenerative diseases, targeting EVs or manipulating the nature of EVs as natural 
carriers of miRNAs and drug delivery devices. It has been investigated that EVs as 
biomarkers of CNS disorders as well as therapeutic agents (197). Also, targeting EVs directly 
to sites for inhibiting deleterious effects seems an attractive approach. Adeno-associated 
viruses (AAVs) encapsulated in EVs with viral capsid proteins can deliver genetic cargo into 
recipient cells (198). EV-mediated delivery offers multiple advantages as these vesicles are 
biocompatible, can be autologous (i.e. patient-derived) and appear to use as the novel weapon 
for the treatment of TBI according to its advantages such as nanosize, easy administration 
and notably ability to cross the biological barriers especially the brain barrier. In a study of 
EVs as a vehicle, EVs loading with siRNA by electroporation and engineered to expose a 
brain-specific peptide (rabies virus glycoproteinderived peptide), specific mRNA knockdown 
was observed throughout the brain but was minor in the liver and spleen. The therapeutic 
potential of EV-mediated siRNA delivery was demonstrated by protein (62%) knockdown of 
BACE1, a therapeutic target in Alzheimer’s disease (143). In another research for therapy 
approach in Alzheimer’s disease with an aspect of increase in antibodies against ceramide, 
Dinkins et al. administrated subcutaneous ceramide injections to increase serum anti-
ceramide IgG in mice animal model and circulating exosomes and finally aid exosome-
mediated clearance of Aβ (199). In neurodegenerative disorders, neurons, and in some cases 
astrocytes, produce and release aggregated proteins such as a-synuclein, amyloid precursor 
protein (APP) and phosphorylated tau and, pathogenic PrPSc protein, inprion disorders. In 
demyelinating disease, myelin-stressed oligodendrocytes produce altered myelin proteins and 
heat shock proteins (HSPs) that may hypothetically be released in EVs. The ‘disease-
associated’ proteins activate microglia that may intense disease or alternatively affects 
neurons and axons leading to dysfunction. Despite the current realization that siRNA loading 
into EVs has although many technical difficulties need to be overcome, targeting of EVs to 
the brain, a major previous biological barrier, seems at least possible. In another recent study, 
intrastriatal injection of exosome-mediated transfer of miRNA (in particular, miR-124a) was 
shown to have a role in neuron to astrocyte signaling. In the research of ALS therapy, 
exosomes isolated from a neuron in conditioned medium which contained small RNAs and 
internalized into astrocytes, increased astrocyte miR-124a and GLT1 protein levels in ALS. 
MiR-124a is selectively reduced in the spinal cord tissue of end-stage mouse model of ALS. 
In addition, exogenous delivery of miR-124a in vivo through stereotaxic injection seemed to 
prevent further pathological loss of GLT1 proteins in animal model (200). Traumatic brain 
injury (TBI) is a leading cause of death and long term disability such as behavioral, cognitive 
and motor deficits worldwide. At present, there are mainly two therapeutic strategies to treat 
TBI; one is a neuroprotective and neurorestorative treatment. In first,  focus on reducing or 
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preventing secondary injury and neural cell death and, the second is to improve neurological 
recovery in CNS to promote neurovascular remodeling including angiogenesis, neurogenesis, 
oligodendrogenesis and dendrite or axon outgrowth (162).  
 In the past decade, exosomes as EVs wildly have been used in research of TBI treatment. In 
this respect, EVs contain various miRNAs which play a key role in modifying the phenotype 
and/or the physiology and modulating the cellular processes of the recipient cell, and 
miRNAs such as miR-21 could be potential therapeutic targets for interventions after TBI 
(201). In another study, Katsuda et al. (2013) have provided an important role for ASCs-
derived exosomes in the context of AD, as these express high levels of Neprilysin (NEP), the 
most important Aβ-degrading enzyme in the brain. NEP-loaded exosomes were shown to be 
efficiently transferred to neuroblastoma cells and led to the decrease of both extracellular and 
intracellular Aβ levels. In vitro neurodegeneration model, exosomes released by dental pulp-
derived MSCs on a 3D culture, rescued dopaminergic neurons from 6-OHDA induced 
apoptosis, thereby providing a possible treatment of Parkinson’s disease (202). Based on data 
achieved from continuous intracerebrally injection of exosomes which loaded with Aβ on 
surface glycosphingolipids, nanovesicles transport into microglia in AD mouse brains, result 
in reductions in Aβ pathology in hippocampus and provide a novel therapeutic intervention 
for Alzheimer disease(203). Immunomodulation of neurological disorders by use of EV-
mediated is in primary steps but important in application of EVs in therapeutic approach. and 
effective. For instance, use of EV derived from modified dendritic cells secreting TGF-β1 to 
inhibit the progression of murine experimental  autoimmune encephalomyelitis (204). Lopez-
Verrilli et al. (2016) have recently unraveled the potential of menstrual MSCs (MenSCs) 
exosomal-enriched fraction as therapeutic approach in neurodegenerative pathologies. 
Because MenSC exosomes induced neurite growth in cortical neurons and had a similar 
effect to BM-MSC exosomes on neurite outgrowth of dorsal root ganglia neurons (205). EV 
protein therapy as a novel strategy for delivery of catalase in Parkinson’s disease to reduce 
oxidative stress and thus help neurons to survive is another application of EV, as prodrug 
actives enzymes which can convert a prodrug which crosses the blood–brain barrier into a 
toxic chemotherapeutic drug for schwannomas and gliomas, and the apoptosis-inducing 
enzyme, caspase-1 under a Schwann cell specific promoter for schwannoma (206). In the 
pilot immunotherapy trial for recurrent malignant gliomas, autologous exosomes isolated 
from tumor cells which removed by surgical craniotomy. The isolated cells, treated with an 
investigational new drug (an antisense molecule), that target surface receptor protein, are re-
implanted (encapsulated in a small diffusion chamber) in the abdomen of the patient. Tumor 
cells treated with the antisense molecules, to apoptosis. Released exosomes are full of tumor 
antigens that together with the antisense molecules and could stimulate the immune system 
against tumor recurrence. The patient of this trial is currently processing. (NCT02507583) 
(www.clinicaltrial.gov). EVs study and analysis is an interesting target for the potential 
detection of new therapeutics in regenerative medicine. This potential needs to further 
research in EVs field, as well the study of novel techniques to produce and develop 
engineered EV. 
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12.4. Cardiovascular disease 
Numerous preclinical and clinical studies within the past few years have demonstrated that 
cardiac stem cell-based therapy could be considered as a new and safe therapeutic procedure 
in heart disease. Among different stem cells that have shown beneficial effects MSCs are the 
most promising cells. The accessible and safety of allograft transplantation of these cells 
make them the most popular stem cells in cardiovascular disease therapy.(225) There have 
been several assumptions regarding mechanisms of MSC related cardiac repair, including 
transdifferentiation and cell fusion. However, the magnitude of overall physiological impact 
seems higher than just structural contribution of these transplanted cells. Therefore it is 
claimed that other components secreted by these cells may contribute to the significant 
therapeutic effect induced by these cells (226,227). These assumptions were further 
confirmed by infarct size reduction and cardiac function improvement in animal models after 
injection of CM of MSC and also by injection of vesicular components of the CM(228,229). 
These findings concurred with new discoveries in 2005 demonstrating that the extracellular 
vesicles derived from platelet are able to induce revascularization in chronic cardiac ischemia 
via VEGF secretion stimulation (230). 10 years later published studies showed that extra 
cellular components derived from plasma trigger cardio protective reactions in ischemia-
reperfusion through induction of TLR4 (Toll-like receptor 4) (231). These findings 
encouraged scientists to discover and empower the components of these paracrine factors in 
order to recapitulate the ability of these components to develop cell-free transplant systems 
and hopefully to overcome the problems associated with cellular therapy. Further studies 
indicates that exosomes derived from cardiac progenitor cells mollify cardiomyocyte death in 
a murine model of ischemic-reperfusion (229,232) Besides, cardiospher-derived cells release 
exosomes that exert the same regenerative effect as their cells of origin in left ventricular 
dysfunction(233,234). Likewise, EVs from human embryonic stem cell driven cardiovascular 
progenitor cells improve cardiac function in post infarct heart failure model of murine like 
their cell counterparts (235). Not only are intact EVs considered as an alternative to cellular 
therapy but also the desirable designed or favorably loaded extracellular vesicles are going to 
be more deeply studied and examined. The assumption is that they may weather be designed 
to target the specific cells or used as a cargo to deliver the drugs of interest to the particular 
cells. For instance it has been shown that miR-126 carrying vesicles decrease atherosclerotic 
plaque formation in mice (236). Furthermore, miR-126 vesicles induce angiogenesis after 
vascular injury (237). Besides, sonic hedgehog overexpressing exosome derived from CD34+ 
improve cardiac function (238). Likewise, sonic hedgehog overexpressing exosome derived 
from T-lymphocyte induce neoangiogenesis by NO synthesis pathway stimulation (239). 
Although such studies are scarce particularly in cardiovascular disease the results are 
promising and it resting seems that EVs whether as therapeutic vectors or as therapeutic 
agents are a step forwards in cardiac cell therapy.  
 
12.5. Kidney injury treatment 
EVs secret by numerous cell types into the extracellular space and extensively present 
circulate with our body in fluids and carry some regulatory signals such as mRNA, miRNA, 
proteins, and molecules of signaling. Increasing amounts of observations suggest that the 
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extracellular vesicles have a key role in the cell-to cell signaling, normal development and 
various pathological developments (207). This makes them as an intriguing diagnostic tools 
and an effective treatment strategy for drug delivery system, cell-free vaccines. The recently 
data propose that urinary EXs incorporated in mediationg cell-to-cell communication of 
nephrons and transfer of functional molecules such as aquaporin-2 between cells (208). The 
accessible information suggest, EXs also play a key role in kidney development due to Wnt 
proteins and beta-catenin delivery which are intense mediator of kidney developmentm. 
While the kidney-Exosomes impacts on the ordinary procedures of kidney are not completely 
illustrated, huge parts of EXs have been appeared in the different kidney disease 
improvement. For example, MSCs or Endothelial derived vesicles improved kidney 
regeneration. Biancone et al distributed that the beneficial influences of MSCs on both acute 
and chronic kidney injury was because of their paracrine effects. . Different examinations 
have been endeavored to research their paracrine impacts through MSC-derived EXs. All 
things considered, EXs of MSCs promoted the injured-kidney epithelium of rat by the 
suppression of apoptosis, increase of tubular epithelial cell proliferation (209-211). Different 
investigations have detailed the anti-apoptotic genes up-regulation and apoptotic genes down-
regulation via a mechanism related to RNA transfer. It has likewise been exhibited the 
effective impacts of bone marrow and umbilical-derived EXs on cisplatin-induced 
nephrotoxicity. These EXs induced renal epithelium proliferation and also, reduced Bax level 
with increase Bcl-2 level in order to decrease apoptosis (89, 207). Another intriguing research 
area is kidney tumor EXs that play a key role in tumorigenesis. One experiment shown that in 
a SCID (immunocompromised severe combined immunodeficient) mouse model Renal 
carcinoma stem cells (rCSCs) derived- vesicles promote lung angiogenesis and 
metastasis(212). Also, EXs potential as diagnostic tools for the kidney malfunction 
monitoring has been shown. It's established, the urinary EX components linked to specific 
nephron parts, thus many of these components can be related a certain disease (213). The 
elevated GPRC5B or Fetuin-A, ATF3 amount in the kidney-derived EXs associated with 
AKI disease which be known as AKI diagnostic marker. Some markers such as Promonin-1 
(CD133) found in healthy people which is lost in the end stage of kidney disease. Also, 
protein and RNA examination of urinary EXs demonstrate a non-obtrusive technique to 
diagnose several kidney diseases.In addition, protein and RNA analysis of urinary EXs prove 
a non-invasive method to diagnose several renal diseases. All things considered,  miR-145 
and miR-130a levels have been expanded in patients-bearing diabetic nephropathy, while 
miR-155 and miR-424 sums were diminished. It is realized that EXs include in kidney 
maladies, cancer and even even typical improvement of kidney. In any case, many works 
ought to be done to illustrate the physiological mechanisms of EXs by characterized disease 
mode (214-216) . 
12.6. Respiratory diseases  
MSC derived secretome generally utilizing as a part of preclinical analyses and various 
outcomes has been distributed that show they can be a novel cell-free strategies for lung 
disease treatment. The amazingly expansive measure of studies showed that MSCs 
therapeutics impacts emerge from dissolvable elements discharge. keratinocyten growth 
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factor (KGF)  and angiopoietin-1 derived MSC support the epithelium of alveolar and 
endothelium against injury  in acute lung injury(ALI) models and clinical trials 
[ISRCTN95690673](217). ](217). Other considered investigated the the anti-inflammatory 
effects of other emitted factors such as interleukin-10 (IL-10), prostaglandin-E2 (PGE2), or 
transforming growth factor-β (TGF-β). In other hand, few productions demonstrated that 
helpful effects of MSC condition medium (CM)-cell free strategy is same as MSC cell 
therapy. In the lipopolysaccharide (LPS)induced-ALI model, the administration of MSC-CM 
avoid edema formation through insulin-like growth factor I secretion.(218). Thus, another 
examination demonstrated comparable outcome LPS-induction of ALI in an ex vivo lung of 
human which demonstrated the diminishing of irritation, edema hindrance and maintaining a 
strategic distance from the inundation of neutrophils and alveolar liquid ingestion bringing up 
in the harmed alveolus(219).  In any case, MSC-CM helpful application has limited in light 
of the fact that there in not a standard procedure of precondition, finding ideal organization 
course and clinical dosage.  As of late, clinical MSC-CM using confronted to the lack of 
condition medium institutionalization. To date, some investigators been contemplated the 
MSCs microvesicles therapeutic impacts in lung diseases related to acute inflammation such 
as ALI, pulmonary artery hypertension (PAH) and asthma (220).  These gatherings found that 
Micorvesicles show solid impacts as their stem cell source as therapy .one study by MSC 
MVs have been conducted in a mouse model of ALI that be induced  by  endotoxin . MVs 
could reestablish protein permeability of lung, diminish the neutrophils influx , expanding  
levels of macrophage inflammatory protein-2. At long last, they reduced inflammation and 
avoided the pulmonary edema formation in the damaged sites (221). Gennai et al.[105] did a 
research by MSC MVs which prompt upgrade of alveolar of  alveolar fluid clearance in a 
dose-dependent way, reduced lung weight after perfusion and ventilation and also a 
significant improvement of airway and hemodynamic parameterswhen compared to perfusion 
alone[105]. in addition, anti- CD44 antibody administered with MVS that attenuate these 
influences through internalization of the MVS into damage cells (222). the consequence of 
many investigations propose several mechanism actions of MSC MVs to induce beneficial 
effects in lung disease including:1) pre-condition of MSCs  with an agonist of  toll-like 
receptor 3 stimulate MSCs before MVS secretion then will improve bacteria phagocytosis; 2) 
The cyclooxygenase 2 (COX2) mRNA transfer to activated monocytes by MSC MVs cause 
secretion of PGE2 which resulting in anti-inflammatory M2 phenotype of monocytes; 3)it's 
observed the uptake of MSC MVS using CD44 receptor is critical for their effective 
influences in primary cultures of human monocytes or human alveolar type 2 cells.  the 
experimental finding suggested that MSC MVS effectiveness  can be similar to their parent 
cells so they can consider as a successful substitute for stem cell therapy in ALI and other 
lung disease (223).  
 
13-exosomes and clinical trials 
As of late, the International Society for Extracellular Vesicles (ISEV) demonstrated the EV-
based therapies thought of administrative, clinical and fabricating.. Clinical manufacturing of 
mammalian vesicles employ cell culture methods of primary stem cells or cell lines for 
constantly secretion of EVs. Notwithstanding, their manufacture is same as other biologics 
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because they naturally secreted from various cell types.  The most created field of EVs is 
cancer therapy (224, 225). The vaccine of dendritic cell-derived and tumor-derived exosomes 
is contemplated in Phase 1/2 trials. . Other effective ranges for unmodified EVs application 
MSCs, endothelial progenitors, Tregs, DCs, and NSCs, as well as of different cell types, are 
regenerative medicine and immunotherapy of non-malignant disorders. Exosomes derived 
from mesenchymal stromal cells are obtaining to the first clinical trials. At least 3 companies 
(ReNeuron, Capricor and Aegle Therapeutics) are developing commercial use of EVs. 
Capricor Inc., investigating their beneficial applications in cardiac and muscle disease 
(http://capricor.com) and ReNeuron Group PLC, , had practical experience in neurological 
and ischemic conditions (http://www.reneuron.com). Moreover, Anosys Inc., began to make 
up autologous DC-derived EVs vaccine for cancer therapy (http://chromos.com). 
Nonetheless, it is essential to mention advantages and disadvantages, while cell lines 
characterization are still not completely understood but primary cells studies have been 
shown many aspects of their capacities to avoid the immunological rejection (226), which in 
some cases have been reduced by autologous EVs application (227, 228).  All in all, the 
primary cell bank generation is challenging due to low vesicle yield of these cell types and 
restricted passage number. The Crucell have designed a human cell-line technology to 
evaluate oncogenic potential of these cells. Some recent studies are studying the applied 
potential of EVs derived from non-mammalian cells such as bacteria, yeast and plant cells 
(229). One of the serious problems can be their isolation techniques for more translational 
trials and research studies. There are current strategies including ultrafiltration, 
ultracentrifugation or a polyethylene glycol 6000 precipitation method (229).  However, the 
contamination of EVs together proteins or lipoproteins occurs which reduce our isolation 
purity level. Overcoming these problems, we need some reproducible methods that isolate 
functional EVs rapidly without any contaminations. Finally, translation of EVs into clinic 
needs isotonic buffers to keep PH shifts during storage process such as freezing and thawing. 
The optimization and validation of storage condition will conduct stability of their function 
and physical characteristics. Also, the temperature storage and certain materials for long-time 
reservation must be established since they are most effective on the reserved sample quality 
(230). 
 
14. Conclusion 
Although the therapeutic benefits of MSCs in immune modulation and tissue remodeling 
have drawn much interest, there are several limitations that impair their wide widespread use. 
It has been demonstrated that implanted MSCs do not survive for long time and the MSCs 
therapeutic benefits might be attributable to their secreted factors including cytokines, growth 
factors, microRNAs, proteasomes, and exosomes, which may play an important role in the 
regulation of numerous physiological processes (231) . Secretome-based approaches using 
exosomes may present considerable potential advantages over living cells; multiple 
experimental studies demonstrate that secretome-derived products are sufficient to 
significantly improve multiple biomarkers of pathophysiology in many animal models of 
different diseases. Various studies indicate that MSC-derived exosomes exert their effect via 
horizontal transfer of proteins, mRNAs and regulatory microRNAs. Anatomical origin of 
MSC changes the composition and effects of secretomes. For instance, hUCESCs are 
obtained by Pap cervical smear, so the quick obtain of large amounts of hUCESCs or 
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secretome-derived products for research and clinical use is ossible because of their easy 
isolation and high proliferative rate (232) . The complex composition of secretome-derived 
products from MSCs should not be an impediment for regulatory approval of a regenerative 
product. For example, platelet-rich plasma or amniotic fluid, which are routinely used as a 
regenerative therapy for multiple applications in wound healing and orthopedics include 
numerous growth factors and exosomes that have not completely characterized. Exosomes 
sourced from dendritic cells are used in the clinical-trial stage for immunotherapy of certain 
cancers even though the regulatory requirements for manufacturing and quality control are 
required. Safety tests will be based on systemic bio-distribution, biocompatibility and half-
life trials (233). Despite the rapid progress in exosome research, a number of important 
questions remain about their role in MSC biology; including the role that endogenous niche 
resident MSCs, which secrete exosomes or microvesicles, play in hematopoiesis and skeletal 
homeostasis, as well as their role in niche maintenance under normal physiological 
conditions, the possibility of captured MSC by its secreted products for therapeutically use. 
But these problems are some of the most interesting problems in biology that do not confined 
to MSCs or stem cells but the broader biology community will contribute to answer. MSC-
derived exosomes use has several potential advantages in human patients. First, it avoids 
transfer of cells which may have mutated or damaged DNA. Second, against MSCs which are 
too large, exosomes are small to circulate easily through capillaries. Third, while the dose of 
infused MSCs quickly diminishes, it is possible that MSC-derived vesicles can deliver a 
higher “dose” and circulates to a greater extent. Furthermore, their cost-effective strategies 
and possible repeated administration have been though as their advantages. However, MSC-
derived are static and more cannot be produced in vivo when the cell is transplanting (155). 
Several significant parameters affect the utility and efficacy of MSC-derived exosomes 
clinical testing including optimizing reproducible methods to manufacture exosomes/ 
microvesicles with defined content, developing methods of storage and recovery of these 
products that maintain vesicle potency, and evaluating their therapeutic efficacy in well 
controlled, appropriately powered clinical trials that are rationally designed based on 
supporting scientific and translational data.  Still, there are a number of challenges that need 
to be resolved prior to their clinical application. The amount of MSC exosomes needed to 
generate an equivalent effect as MSCs in tissue injury is roughly higher. Although MSCs are 
relatively easy to expand in vitro, their growth in culture is finite, so new batches of MSCs 
and more effective techniques for large-scale exosome production need to be developed 
(229). Furthermore, since there is still no gold standard in characterizing MSC exosomes, the 
obtained exosomes isolated are also heterogeneous which may cause different effects on their 
target cells. Moreover, as the methods used to precondition MSC in stimulating exosome 
release change the surface and their intracellular content, the effective methods for 
maintaining the homogeneity of MSC-derived exosomes need to be developed. 
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Figure legend: 
 
Figure 1. An overview of different extracellular vesicle (EXs  ( , exosomes and microvesicles 
(MVs) loading techniques. Left panel: loading of EVs after their isolation via common loading 
methods (electroporation, incubation, sonication, extrusion, etc.). Right panels: loading of EVs via 
treatment/transfection of the parental cells. 
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Table 1 Overview of therapeutic applications of EV-based gene delivery 
 
Type/source of EV Loading 
method 
Target gene/cells Drug 
(nucleic 
acid  
biotype) 
Target  effects Ref. 
Rat heart-derived 
H9c2 
Transfection  QKI  miR- 
208a/b 
Suppress apoptosis of 
cardiomyocyte 
 
(234) 
Human endothelial 
cells 
Transfection   5-
hydroxytryptamin
e transporter (5-
HTT) 
 miR-195 regulation of the 
proliferation of Human 
smooth muscle cells through 
5-HTT 
(235) 
Adipose-derived Stem 
Cells 
Transfection  WISP2  miR-450a-
5p 
miR-450a-5p promoted 
adipogenesis through 
repressing expression of 
WISP2 
(236) 
human Wharton Jelly 
mesenchymal stromal 
cells 
Transfection  DRP1/ Rat renal 
tubular epithelial 
cells 
 mir-30 ameliorate acute renal IRI 
by inhibiting mitochondrial 
fission  
(237) 
human liver stellate 
cell line (LX2) 
Transfection  VEGF, CDC42, 
CDK1,CDK4, 
CDK6, and 
CDC25/BDEneu 
and BDEsp cell 
line 
 mir-195 decrease the size of 
cholangio carcinoma tumor, 
and improve survival of 
treated rats 
(238) 
HUVEC cells Transfection  VEGF/Human 
gastric cell line 
SGC7901 
mir-29a/c miRNA-containing MVs to 
control gastric cancer 
growth by blocking 
angiogenesis 
(144) 
adipose-derived stem 
cells microvesicles 
Transfection  factor-inhibiting 
HIF-1/ HUVECs 
mir-31 angiogenic therapy for 
ischemic diseases 
(239) 
adipose-derived stem 
cells exosomes 
Transfection  ADAM10, 
IGF1R, and 
CCNG1/ 
Hepatocellular 
carcinoma 
miR-122 enhance HCC 
chemosensitivity 
(240) 
WT-MSCs exosomes Transfection Sema3A and 
Stat3/ 
cardiomyocytes 
miR-223 exosomal miR-223 induced 
cardio-protection in sepsis 
(241) 
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
Pancreatic cancer-
derived exosomes 
Transfection RFXAP miR-212-
3p 
miR-212-3p 
transferred to dendritic 
cells & 
decrease MHC II expression 
and induce immune 
tolerance of dendritic cells 
(242) 
Mesenchymal stem 
cells exosomes 
Transfection Efna3/ HUVECs miR-210 MSC-EVs significantly 
improved angiogenesis and 
cardiac function in post-MI 
heart 
(243) 
HEK293T, 
HUVEC,HRVT, 
hMSC 
Electroporation HEK293Ts 1000>bp 
dsDNA 
from the 
VA1 gene 
EVs as broadly applicable 
DNA delivery vehicles 
(139) 
HBV-infected PXB-
cells 
Inoculation with 
HBV 
HBV -DNA  transmitting viral DNA into 
hepatocytes 
(134) 
human  glioma cancer 
stem cells 
Transfection Bloodstream  DNA 
sequence 
of 
IDH1G395 
mutation 
EVs can cross the disrupted 
BBB into the bloodstream 
(137) 
HL-1, acardiomyocyte 
cell line 
Transfection Fibroblasts DNA gene expression changes (138) 
Cardiosphere-derived 
cells 
Exo-Fect 
exosome 
transfection 
Macrophages  Y RNA 
fragment 
cardioprotection via 
modulation of IL-10 
expression 
and secretion 
(141) 
brain endothelial 
bEND.3 
Transfection  U-87 MG cells VEGF 
siRNA 
brain tumor (244) 
Human  keratinocytes Transfection Melanocytes  
and/or fibroblasts 
miR-675 miR-675 inhibit 
melanogenesis 
(245) 
ES-2 and SKOV3 Transfection RMG-1, ES-2 and 
A2780 cell lines 
MMP1 ovarian cancers (246) 
U87 glioblastoma cells Exosome were 
incubate with 
Cy3- fluorescent 
hsiRNAs 
Primary cortical 
neurons were 
isolated from 
E15.5 mouse 
hsiRNAs 
targeting 
Huntingtin 
mRNA 
Huntington's disease (142) 
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HEK-293T cells Transfection Human 
schwannoma cell 
line HEI-193 
Cytosine 
deaminase- 
uracil 
phosphorib
osyltransfe
rase 
schwannoma tumors (140) 
The HEK 293T and 
CHO-K1 cells 
Transfection Rat primary 
pinealocyte cells 
siRNA for 
the 
endogenou
s GTPBP1 
exosome-mediated mRNA 
turnover 
pathway 
(247) 
Bone marrow 
mesenchymal stem 
cells 
Transfection Intestinal 
epithelial cells: 
IEC-6 
miR-200b anti-fibrotic treatment (248) 
MDA-MB-231 (breast) 
cancer cells 
Transfection Fibroblasts miR-9 enhancing the switch to 
CAF phenotype 
(249) 
U87 and X12 cells Transfection Brain 
microvascular 
endothelial cells 
(HBMVEC) 
miR-1 Reduce GBM invasion (250) 
human MCF-7 and 
MDA-MB-231 cells 
transfection HMLE cells miR-10b induce the invasion ability 
of non-malignant HMLE 
cells 
(251) 
Murine dendritic 
Cells 
Electroporation Systemic delivery 
to mice 
α-Syn 
siRNA 
Parkinson's disease (252) 
HEK-293T Transfection C2C12 cell lines MOR 
siRNA 
morphine addiction (151) 
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